Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXASNASDAQ:FOLDNASDAQ:HALONASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$42.55-3.9%$48.64$40.62▼$74.44$7.90B1.142.58 million shs4.62 million shsFOLDAmicus Therapeutics$7.50-6.3%$9.12$7.39▼$12.65$2.30B0.692.54 million shs3.18 million shsHALOHalozyme Therapeutics$59.77-3.5%$59.82$37.73▼$66.00$7.38B1.321.39 million shs2.30 million shsMDGLMadrigal Pharmaceuticals$314.39-3.9%$333.68$189.00▼$377.46$6.94B-0.68388,636 shs343,494 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences-3.91%-2.54%-10.67%-25.68%-41.57%FOLDAmicus Therapeutics-6.25%-11.03%-18.03%-20.30%-34.04%HALOHalozyme Therapeutics-3.47%-6.38%+0.40%+25.20%+48.57%MDGLMadrigal Pharmaceuticals-3.89%-4.11%-9.47%-1.66%+28.20%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXASExact Sciences4.3532 of 5 stars4.52.00.04.72.71.70.6FOLDAmicus Therapeutics4.1204 of 5 stars3.41.00.04.34.00.81.9HALOHalozyme Therapeutics4.1207 of 5 stars1.31.00.04.43.52.54.4MDGLMadrigal Pharmaceuticals3.3189 of 5 stars2.40.00.04.62.44.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXASExact Sciences 2.90Moderate Buy$70.2665.13% UpsideFOLDAmicus Therapeutics 2.78Moderate Buy$16.75123.33% UpsideHALOHalozyme Therapeutics 2.60Moderate Buy$62.785.03% UpsideMDGLMadrigal Pharmaceuticals 2.80Moderate Buy$378.4420.37% UpsideCurrent Analyst Ratings BreakdownLatest FOLD, EXAS, HALO, and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025EXASExact SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.003/13/2025EXASExact SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$52.003/6/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/27/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$236.00 ➝ $422.002/27/2025MDGLMadrigal PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$378.00 ➝ $469.002/27/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$400.00 ➝ $405.002/26/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.002/24/2025EXASExact SciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$70.00 ➝ $73.002/20/2025EXASExact SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/20/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$70.00 ➝ $65.002/20/2025EXASExact SciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $65.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXASExact Sciences$2.76B2.86$4.84 per share8.79$12.93 per share3.29FOLDAmicus Therapeutics$528.30M4.36N/AN/A$0.63 per share11.90HALOHalozyme Therapeutics$1.02B7.27$4.84 per share12.35$2.95 per share20.26MDGLMadrigal Pharmaceuticals$180.13M38.54N/AN/A$20.53 per share15.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXASExact Sciences-$204.15M-$5.57N/A85.10N/A-37.29%-5.29%-2.45%5/1/2025 (Estimated)FOLDAmicus Therapeutics-$151.58M-$0.18N/A17.441.51-10.62%12.44%2.60%5/8/2025 (Estimated)HALOHalozyme Therapeutics$281.59M$3.4317.439.610.4243.74%157.78%25.34%5/6/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$22.11N/AN/AN/AN/A-71.78%-53.25%5/6/2025 (Estimated)Latest FOLD, EXAS, HALO, and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/AEXASExact Sciences-$0.35N/AN/AN/A$688.58 millionN/A2/26/2025Q4 2024MDGLMadrigal Pharmaceuticals-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 million2/19/2025Q4 2024EXASExact Sciences-$0.29-$0.06+$0.23-$4.67$701.45 million$713.42 million2/18/2025Q4 2024HALOHalozyme Therapeutics$1.17$1.19+$0.02$1.06$285.74 million$298.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXASExact SciencesN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXASExact Sciences0.972.151.93FOLDAmicus Therapeutics2.013.392.42HALOHalozyme Therapeutics4.147.809.15MDGLMadrigal Pharmaceuticals0.155.985.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXASExact Sciences88.82%FOLDAmicus TherapeuticsN/AHALOHalozyme Therapeutics97.79%MDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipEXASExact Sciences1.36%FOLDAmicus Therapeutics2.20%HALOHalozyme Therapeutics2.90%MDGLMadrigal Pharmaceuticals22.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXASExact Sciences6,400185.76 million182.56 millionOptionableFOLDAmicus Therapeutics480307.24 million292.23 millionOptionableHALOHalozyme Therapeutics390123.53 million120.20 millionOptionableMDGLMadrigal Pharmaceuticals9022.08 million16.84 millionOptionableFOLD, EXAS, HALO, and MDGL HeadlinesRecent News About These CompaniesBryce Point Capital LLC Buys Shares of 1,903 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 5 at 5:39 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Purchased by Groupama Asset ManagmentApril 3 at 6:16 AM | marketbeat.comVanguard Group Inc. Sells 127,633 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 2 at 3:57 AM | marketbeat.comKLP Kapitalforvaltning AS Invests $802,000 in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 2 at 3:49 AM | marketbeat.comPictet Asset Management Holding SA Buys 57,886 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 31, 2025 | marketbeat.comNEOS Investment Management LLC Decreases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 31, 2025 | marketbeat.comArtisan Partners Limited Partnership Trims Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 29, 2025 | marketbeat.comAmerican Century Companies Inc. Grows Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 29, 2025 | marketbeat.comIs Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?March 28, 2025 | insidermonkey.comMadrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?March 28, 2025 | zacks.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $378.44 Average PT from BrokeragesMarch 26, 2025 | americanbankingnews.comKnights of Columbus Asset Advisors LLC Buys 2,116 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 24, 2025 | marketbeat.comCibc World Markets Corp Makes New $519,000 Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 23, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Recommendation of "Moderate Buy" from AnalystsMarch 23, 2025 | marketbeat.comMadrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comWilliam Blair Investment Management LLC Purchases Shares of 371,771 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 18, 2025 | marketbeat.comRaymond James Financial Inc. Takes $16.62 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 18, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Has $2.43 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 17, 2025 | marketbeat.comProficio Capital Partners LLC Acquires New Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 17, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $46.52 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 15, 2025 | marketbeat.comMadrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potentialMarch 14, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military Spending3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow MarginsBy Leo Miller | March 19, 2025View 3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow MarginsFOLD, EXAS, HALO, and MDGL Company DescriptionsExact Sciences NASDAQ:EXAS$42.55 -1.73 (-3.91%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$42.40 -0.15 (-0.35%) As of 04/4/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Amicus Therapeutics NASDAQ:FOLD$7.50 -0.50 (-6.25%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$7.66 +0.16 (+2.15%) As of 04/4/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Halozyme Therapeutics NASDAQ:HALO$59.77 -2.15 (-3.47%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$59.22 -0.56 (-0.93%) As of 04/4/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Madrigal Pharmaceuticals NASDAQ:MDGL$314.39 -12.71 (-3.89%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$299.69 -14.70 (-4.68%) As of 04/4/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
